Summit Therapeutics (SMMT) Osake Kurssi

Summit Therapeutics Inc is primarily active in the pharmaceutical industry. With a focus on developing innovative therapies, Summit Therapeutics engages in drug discovery and development for various medical conditions. The company's expertise lies in the research and development of novel antibiotics, specifically targeting the treatment of bacterial infections. Summit Therapeutics works closely with healthcare professionals and regulatory agencies to bring safe and effective therapeutic solutions to patients in need. As a leading player in the pharmaceutical industry, Summit Therapeutics Inc continuously strives to enhance healthcare outcomes and improve the quality of life for individuals worldwide.

The main competitors of Summit Therapeutics Inc in the market include pharmaceutical companies such as AstraZeneca, Pfizer, Novartis, and GlaxoSmithKline.

Summit Therapeutics Inc is a renowned biotechnology company specializing in developing innovative medicines for patients with rare diseases. Founded in 2003, Summit Therapeutics has made significant strides in the field of precision medicine. With a strong focus on genetic diseases, the company uses its proprietary technologies to discover and advance promising therapeutics options. Summit Therapeutics Inc has a track record of successful collaborations with renowned academic institutions and pharmaceutical companies, diversifying its pipeline and expanding its research capabilities. By combining cutting-edge science and strategic partnerships, Summit Therapeutics strives to improve the lives of patients worldwide with groundbreaking treatments and therapies.

Summit Therapeutics Inc has achieved several significant milestones. The company successfully completed Phase II clinical trials for its lead antibiotic candidate, Ridinilazole, demonstrating its effectiveness in treating Clostridium difficile infection. Summit Therapeutics also received Fast Track designation from the U.S. FDA for Ridinilazole, speeding up the review process. In addition, the company secured a collaboration with the Bill & Melinda Gates Foundation to develop new antibiotics targeting gonorrhea, emphasizing their commitment to addressing antimicrobial resistance. Moreover, Summit Therapeutics listed on NASDAQ exchange, enhancing its visibility and accessibility to investors. These milestones highlight the company's progress and dedication to advancing innovative therapies to address unmet medical needs.

Summit Therapeutics Inc is primarily present in the United States and the United Kingdom. They have established their headquarters in Cambridge, Massachusetts, USA, and have an additional office in Oxfordshire, England. The company specializes in the discovery and development of novel medicines to treat rare diseases and infectious diseases. With a focus on innovative research and collaboration, Summit Therapeutics Inc aims to deliver transformative therapies that address significant unmet medical needs.

Summit Therapeutics Inc represents values of innovation, dedication, and commitment to improving patient outcomes. With a strong corporate philosophy focused on advancing breakthrough treatments, Summit is renowned for its cutting-edge research and development initiatives in the pharmaceutical industry. The company strives to leverage its expertise and strategic partnerships to deliver high-quality therapies and address unmet medical needs. Summit Therapeutics Inc's commitment to scientific excellence and patient-centric approach makes it an industry leader, dedicated to transforming healthcare and making a positive impact on people's lives.

Analyytikot asettavat tällä hetkellä Summit Therapeutics-osakkeelle keskimääräisen tavoitehinnan 26,00 USD (mediaani: 23,00 USD), mikä merkitsee +64,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 24 analyytikkoarvioon.

Summit Therapeutics Analyytikkojen kursstavoitteet 2026

24 analyytikkoa arvioi tällä hetkellä Summit Therapeutics-osaketta: 17 suosittaa ostoa, 7 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Summit Therapeutics-yhtiöltä 3,66 M USD liikevaihtoa ja −1,16 USD osakekohtaista tulosta.

Summit Therapeutics Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Summit Therapeutics-osake noteerataan hintaan 14,06 EUR (15,80 USD).

Summit Therapeutics-osake (SMMT) on listattuna 1 pörssissä, muun muassa: NASDAQ (SMMT).

Summit Therapeutics Inc. is a biopharmaceutical company specializing in the discovery and development of innovative therapeutic options for rare diseases. The company is headquartered in Oxford, United Kingdom, and also operates locations in the United States. The business model of Summit Therapeutics primarily focuses on identifying and developing medical treatment options for genetically inherited diseases. The company combines comprehensive research and development, strategic partnerships, and careful market research to offer a wide range of products and services. Summit Therapeutics' research area is dedicated to identifying biomarkers and disease mechanisms that play a role in rare diseases. The company utilizes cutting-edge technology and analytical approaches to advance groundbreaking developments in this field. Summit Therapeutics also collaborates closely with external partners to exchange resources and expertise and create synergies. The company has strategic partnerships with leading institutions such as the Children's Hospital of Philadelphia and the University of Oxford, as well as biotech and pharmaceutical companies like Japanese company Sarepta and Swiss company Lonza. Summit Therapeutics' products include a range of drugs in the clinical development stage for the treatment of neuromuscular disorders such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). The company also has an active research branch focused on developing drugs to combat diseases such as C. difficile infections and cystic fibrosis. In addition to these core activities, Summit Therapeutics also offers a wide range of services including consulting, drug discovery platforms, partnering, and clinical development. These services are tailored to the needs of pharmaceutical companies and academic institutions, aiming to accelerate their research and development activities. Overall, Summit Therapeutics has a differentiated business model focused on identifying and developing therapeutic options for rare diseases. The company strives to be a leader in this field by leveraging its innovative research and strategic partnerships to offer a wide range of products and services.

odotettu liikevaihto Summit Therapeutics on 3,66 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Summit Therapeutics on −833,57 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Summit Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −13,62. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Summit Therapeutics-osakkeen arvostusta.

Summit Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 3 105,18. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Summit Therapeutics-osakkeen arvostuskennuslukuna.

Summit Therapeutics:n Eulpool-laatuscore on 3/10.

Summit Therapeutics:n ISIN on US86627T1088. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Summit Therapeutics:n ticker on SMMT. Tämä pörssinoteeraus käytetään Summit Therapeutics-osakkeiden kauppaan pörssissä.